| ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable colorectal cancer A Mehrvarz Sarshekeh, J Alshenaifi, J Roszik, GC Manyam, SM Advani, ... Clinical Cancer Research 27 (6), 1663-1670, 2021 | 38 | 2021 |
| Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer E Orouji, AT Raman, AK Singh, A Sorokin, E Arslan, AK Ghosh, J Schulz, ... Gut 71 (5), 938-949, 2022 | 33 | 2022 |
| Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy CM Parseghian, R Sun, M Woods, S Napolitano, HM Lee, J Alshenaifi, ... Journal of Clinical Oncology 41 (3), 460-471, 2023 | 29 | 2023 |
| Evolving strategies for the management of BRAF-mutant metastatic colorectal cancer. HM Lee, V Morris, S Napolitano, S Kopetz Oncology (08909091) 33 (6), 2019 | 14 | 2019 |
| Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers JA Klomp, JE Klomp, CA Stalnecker, KL Bryant, AC Edwards, ... Science 384 (6700), eadk0775, 2024 | 6 | 2024 |
| Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer S Napolitano, M Woods, HM Lee, V De Falco, G Martini, CM Della Corte, ... Clinical Cancer Research 29 (12), 2299-2309, 2023 | 6 | 2023 |
| YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer O Coker, A Sorokin, N Akhave, K Pan, F Gao, Z Liu, P Kanikarla, HM Lee, ... Cancer Research 84 (6_Supplement), 1937-1937, 2024 | | 2024 |
| ASCL2+ tumor cells modulate the response of colorectal cancer to MAPK targeting therapy OE Villarreal, HM Lee, H Tran, A Machado, J Alshenaifi, CW Wong, ... Cancer Research 84 (6_Supplement), 3280-3280, 2024 | | 2024 |
| Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer HM Lee, AK Saw, VK Morris, AK Singh, S Napolitano, A Sorokin, PK Marie, ... Cancer Research 84 (6_Supplement), 3241-3241, 2024 | | 2024 |
| Epigenetic Modification as a Therapeutic Target in BRAFV600E-mutated Metastatic Colorectal Cancer HM Lee | | 2024 |
| Antitumor Efficacy of Dual Blockade with Encorafenib+ Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer M Woods, HM Lee, V De Falco, G MARTINI, CM Della Corte, S Napolitano, ... American Association for Cancer Research, 2023 | | 2023 |
| Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer HM Lee, A Sorokin, PK Marie, S Chowdhury, A Singh, A Anderson, ... Cancer Research 83 (7_Supplement), 5486-5486, 2023 | | 2023 |
| Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies HM Lee, S Napolitano, A Sorokin, MN Woods, S Chowdhury, ... Cancer Research 82 (12_Supplement), 3275-3275, 2022 | | 2022 |
| Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models. MN Woods, V De Falco, C Prisco, G Martini, LP Guerrera, V Belli, ... Journal of Clinical Oncology 40 (4_suppl), 145-145, 2022 | | 2022 |
| Abstract LB264: Oncogenic KRASG12C dependency in colorectal cancer O Coker, A Sorokin, K Gale, F Gao, JP Shen, L Kwong, J Wu, HM Lee, ... Cancer Research 81 (13_Supplement), LB264-LB264, 2021 | | 2021 |
| Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. HM Lee, S Napolitano, VK Morris, K Rai, JPYC Shen, JS Davis, DM Maru, ... Journal of Clinical Oncology 39 (3_suppl), 110-110, 2021 | | 2021 |
